PRESS RELEASE
Published February 21, 2023
Las Vegas, Nevada, United States, DelveInsight’s “Diffuse Intrinsic Pontine Glioma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology of Diffuse Intrinsic Pontine Glioma as well as the market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Diffuse Intrinsic Pontine Glioma Overview
According to the National Cancer Institute, Diffuse Intrinsic Pontine Glioma (DIPG: also known as Diffuse Midline Glioma are primary central nervous system tumor. This means they begin in the brain or spinal cord. It is a rare subtype of glial tumor and is considered a Grade IV tumor. Diffuse Intrinsic Pontine Glioma harboring the H3 K27M are lethal high-grade pediatric brain tumors that are inoperable and without a cure. DIPGs are all Grade IV tumors, which means they are malignant (cancerous) and fast-growing.
The majority of these tumors are found in the brainstem (which controls many critical functions like breathing, swallowing, and heart rate), but can also be found in other midline structures like the thalamus and spinal cord. It is worth noting that brainstem tumors and tumors of the thalamus, as well as the spinal cord, were a part of DIPG but now are categorized in the DMG group. DMG primarily affects children, but can occasionally be found in adults as well
Leading Companies Working in the Diffuse Intrinsic Pontine Glioma Market
Regeneron Pharmaceuticals
Bexion Pharma
Pfizer
Nector Therapeutics
Aminex Therapeutics
AbbVie
And many others
Promising Therapies in the Diffuse Intrinsic Pontine Glioma Pipeline
ONC201
BXQ-350
DNX-2401
Paxalisib
Omburtamab
PTC596
And many others
Learn more about the key companies and emerging therapies @ Diffuse Intrinsic Pontine Glioma Therapeutics Market Analysis
Diffuse Intrinsic Pontine Glioma Market Assessment by DelveInsight
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Diffuse Intrinsic Pontine Glioma market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives complete detail of the Diffuse Intrinsic Pontine Glioma market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Learn how the market will evolve by 2032 @ Diffuse Intrinsic Pontine Glioma Market Trends and Growth Analysis
Scope of the Diffuse Intrinsic Pontine Glioma Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, Japan]
Key Diffuse Intrinsic Pontine Glioma Companies: Gilead Biosciences, Eiger BioPharmaceuticals, Roche Pharmaceuticals, Merck, and many others.
Key Diffuse Intrinsic Pontine Glioma Pipeline Therapies: Bulevirtide, Myrcludex B, lonafarnib, Ritonavir, and many others.
Therapeutic Assessment: Diffuse Intrinsic Pontine Glioma current marketed and emerging therapies
Diffuse Intrinsic Pontine Glioma Market Dynamics: Diffuse Intrinsic Pontine Glioma market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Diffuse Intrinsic Pontine Glioma Market Access and Reimbursement
Table of Contents
1. Diffuse Intrinsic Pontine Glioma Market Key Insights
2. Diffuse Intrinsic Pontine Glioma Market Report Introduction
3. Diffuse Intrinsic Pontine Glioma Market Overview at a Glance
4. Diffuse Intrinsic Pontine Glioma Market Executive Summary
5. Disease Background and Overview
6. Diffuse Intrinsic Pontine Glioma Treatment and Management
7. Diffuse Intrinsic Pontine Glioma Epidemiology and Patient Population
8. Patient Journey
9. Diffuse Intrinsic Pontine Glioma Emerging Drugs
10. 7MM Diffuse Intrinsic Pontine Glioma Market Analysis
11. Diffuse Intrinsic Pontine Glioma Market Outlook
12. The potential of Current and Emerging Therapies
13. KOL Views
14. Diffuse Intrinsic Pontine Glioma Market Drivers
15. Diffuse Intrinsic Pontine Glioma Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Download the sample pages @ Diffuse Intrinsic Pontine Glioma Market Outlook
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Contact Us
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: [email protected]
City: Albany
State: New York
Country: United States
Website: www.delveinsight.com
